• In March 2026, Zai Lab announced that three internally-developed oncology candidates, zocilurtatug pelitecan (zoci), ZL-6201, and ZL-1222, were presented across four poster sessions at the American Association for Cancer Research Annual Meeting 2026 in San Diego, highlighting progress in small cell lung cancer, sarcoma, and immuno-oncology programs.
• The company also outlined plans for three registration-enabling studies for zoci by the end of 2026, signaling its intent to position this DLL3-targeting antibody-drug conjugate as a potential new standard of care in extensive-stage small cell lung cancer and extrapulmonary neuroendocrine carcinomas.
• We’ll now examine how advancing zoci toward three planned registration-enabling studies could influence Zai Lab’s previously outlined growth narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Zai Lab Investment Narrative Recap

To own Zai Lab, you need to believe its oncology and immunology pipeline can eventually convert heavy R&D spend into durable, global revenue despite ongoing losses and China pricing pressures. The key near term catalyst is whether zocilurtatug pelitecan (zoci) can move cleanly into three registration enabling studies by the end of 2026. The AACR data and study plans support that timeline, but they do not remove the core risk that high costs and intense competition could still delay a path to sustainable profitability.

Among recent updates, the 2025 results matter most here: Zai Lab reported Q4 2025 revenue of US$127.6 million and a narrowed net loss of US$50.41 million, while reiterating full year 2025 revenue guidance of US$560 million to US$590 million. Against this backdrop, advancing zoci and the broader internal oncology pipeline, highlighted at AACR 2026, becomes central to whether future revenue can grow fast enough to justify continued investment in these programs.

Yet beneath the excitement around zoci and AACR data, investors should be aware of how rising R&D costs could collide with...

Zai Lab's narrative projects $1.5 billion revenue and $250.1 million earnings by 2028.

Uncover how Zai Lab's forecasts yield a $49.49 fair value, a 171% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming about US$1.3 billion of 2028 revenue and only US$37.4 million of earnings, so you should expect that the new zoci data and global ambitions could either soften or reinforce their concern that heavy reliance on pipeline approvals and China reimbursement leaves far less room for disappointment than the consensus view implies.

Explore 4 other fair value estimates on Zai Lab - why the stock might be worth just $20.42!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zai Lab research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zai Lab research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zai Lab's overall financial health at a glance.

No Opportunity In Zai Lab?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.